Correction to: Leukemia https://doi.org/10.1038/s41375-021-01297-z, published online 21 May 2021
The Funding information section was missing from this article and should have read ‘This work was supported by the Paul Calabresi K12 Career Development Award (CA90628-21) and in part by Grant Number P30 CA015083 and CA186781 from the National Cancer Institute and by the Predolin Foundation and the JABBS Foundation.’.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Vaxman, I., Kumar, S.K., Buadi, F. et al. Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. Leukemia 38, 1866 (2024). https://doi.org/10.1038/s41375-024-02311-w
Published:
Issue date:
DOI: https://doi.org/10.1038/s41375-024-02311-w
